26. π-Conjugated Porous Polymer Nanosheets for Explosive Sensing: Investigation on the Role of H-Bonding
Saurabh Kumar Rajput, Atul Kapoor, Abhishek Yogi, Venkateswarlu Yarlagadda, Suresh Mothika
Chem. Asian J. 2024, https://doi.org/10.1002/asia.2024009397
25. Exploring the Darobactin Class of Antibiotics: A Comprehensive Review from Discovery to Recent Advancements
Akash Dutta, Peehu Sharma, Dharam Dass, Venkatewarlu Yarlagadda*
ACS Infect. Dis. 2024, 10, 8, 2584–2599
24. A screen of natural product extracts identifies moenomycin as a potent antigonococcal agent
V. Yarlagadda, V. N. Rao, M. Kaur, A. Guitor, G. D. Wright
ACS Infect. Dis. 2021, 7, 1569-1577.
23. Resistance-guided discovery of elfamycin antibiotic producers with antigonococcal activity
V. Yarlagadda, R. Medina, T. Johnson, G. Cox, K. Koteva, M. N. Thaker, G. D. Wright
ACS Infect. Dis. 2020, 6, 12, 3163–3173.
22. Venturicidin, a membrane-active natural product inhibitor of ATP synthase potentiates aminoglycosides antibiotics
V. Yarlagadda, R. Medina, G. D. Wright
Scientific Reports, 2020, 10, 8134.
21. Vancomycin derivative inactivates carbapenem-resistant Acinetobacter baumannii and induces autophagy
P. Sarkar, S. Samaddar, V. Ammanathan, V. Yarlagadda, C. Ghosh, M. Shukla, G. Kaul, R. Manjithaya, S. Chopra, J. Haldar
ACS Chem. Biol. 2020, 15, 884-889.
20. Membrane-active rhamnolipids overcome aminoglycoside resistance
V. Yarlagadda, G. D. Wright
Cell Chem. Biol. 2019, 26, 1333-1334.
19. Vancomycin analogue restores meropenem activity against NDM-1 Gram-negative pathogens
V. Yarlagadda, P. Sarkar, S. Samaddar, G. B. Manjunath, S. D. Mitra, K. Paramanandham, B. R. Shome, J. Haldar
ACS Infect. Dis. 2018, 4, 1093-1101.
18. A vancomycin derivative with a pyrophosphate-binding group: A strategy to combat vancomycin-resistant bacteria. (Highlighted as a "Very important paper" in antibiotics)
V. Yarlagadda, P. Sarkar, S. Samaddar, J. Haldar
Angew. Chem. Int. Ed. 2016, 27, 7836-7840.
17. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics
P. Sarkar, V. Yarlagadda, C. Ghosh, J. Haldar
MedChemComm, 2017, 8, 516-533.
16. Glycopeptide antibiotic to overcome the intrinsic resistance of Gram-negative bacteria
V. Yarlagadda, G. B. Manjunath, P. Sarkar, P. Akkapeddi, K. Paramanandham, S. B. Ranjan, R. Ravikumar, J. Haldar
ACS Infect. Dis. 2016, 2, 132-139.
15. Lipophilic vancomycin aglycon dimer with high activity against vancomycin-resistant bacteria
(Highlighted in Nature India "New defence against superbugs")
http://www.natureasia.com/en/nindia/article/10.1038/nindia.2015.151
V. Yarlagadda, P. Sarkar, G. B. Manjunath, J. Haldar
Bioorg. Med. Chem. Lett. 2015, 25, 5477-5480.
14. Intracellular activity of membrane active glycopeptide antibiotic (YV11455) against MRSA infection
V. Yarlagadda, S. Samaddar, J. Haldar
J. Global Antimicrob. Resist. 2016, 5, 71-74.
13. Membrane disruption and enhanced inhibition of cell-wall biosynthesis: A synergistic approach to tackle vancomycin-resistant bacteria. (Highlighted as a "Hot paper" in drug design).
V. Yarlagadda, S. Samaddar, K. Paramanandham, B. R. Shome, J. Haldar
Angew. Chem. Int. Ed. 2015, 54, 13644-13649.
12. Membrane active small molecules show selective broad spectrum antibacterial activity with no detectable resistance and eradicates biofilms bacteria
J. Hoque, M. M. Konai, S. Gonuguntla, G. B. Manjunath, Sandip Samaddar, V. Yarlagadda, J. Haldar
J. Med. Chem. 2015, 58, 5486-5500.
11. In-vivo efficacy and pharmacological properties of a novel glycopeptide (YV4465) against vancomycin-intermediate Staphylococcus aureus
V. Yarlagadda, M. M. Konai, K. Paramanandham, V. C. Nimitha, B. R. Shome, J. Haldar
Int. J. Antimicrob. Agents 2015, 46, 446-450.
10. Broad spectrum antibacterial and antifungal polymeric paint materials: Synthesis, structure-activity relationship, and membrane-active mode of action
J. Hoque, P. Akkapeddi, V. Yadav, G. B. Manjunath, D. S. S. M. Uppu, M. M. Konai, V. Yarlagadda, K. Sanyal, J. Haldar
ACS Appl. Mater. Interfaces 2015, 7, 1804-1815.
9. Membrane-active macromolecules resensitize NDM-1 Gram-negative clinical isolates to tetracycline antibiotics
D. S. S. M. Uppu, G. B. Manjunath, V. Yarlagadda, J. E. Kaviyil, R. Ravikumar, K. Paramanandham, B. R. Shome, J. Haldar
PLoS ONE 2015, 10, e0119422.
7. Tackling vancomycin-resistant bacteria with 'lipophilic-vancomycin-carbohydrate conjugates'.
V. Yarlagadda, M. M. Konai, G. B. Manjunath, C. Ghosh, J. Haldar
J. Antibiot. 2015, 68, 302-312. IF – 2.649
8. In-vivo antibacterial activity and pharmacological properties of the membrane-active glycopeptide antibiotic YV11455
V. Yarlagadda, M. M. Konai, G. B. Manjunath, R. G. Prakash, B. Mani, K. Paramanandham, S. B. Ranjan, R. Ravikumar, S. P. Chakraborty, S. Roy, J. Haldar
Int. J. Antimicrob. Agents 2015, 45, 627-634.
6. Membrane active phenylalanine conjugated lipophilic norspermidine derivatives with selective antibacterial activity
M. M. Konai, C. Ghosh, V. Yarlagadda, S. Samaddar, J. Haldar
J. Med. Chem. 2014, 57, 9409-9423.
5. Effect of amide bonds on the self-assembly of Gemini surfactants
J. Hoque, S. Gonuguntla, V. Yarlagadda, V. K. Aswal, J. Haldar
Phys. Chem. Chem. Phys. 2014, 16, 11279-11288.
4. Small molecular antibacterial peptoid mimics: The simpler the better!
C. Ghosh, G. B. Manjunath, P. Akkapeddi, V. Yarlagadda, J. Hoque, D. S. S. M. Uppu, M. M. Konai, J. Haldar
J. Med. Chem. 2014, 57, 1428-1436.
3. Membrane active vancomycin analogues: A strategy to combat bacterial resistance
V. Yarlagadda, P. Akkapeddi, G. B. Manjunath, J. Haldar
J. Med. Chem. 2014, 57, 4558-4568.
2. Polymers with tunable side-chain amphiphilicity as non-hemolytic antibacterial agents
D. S. S. M. Uppu, P. Akkapeddi, G. B. Manjunath, V. Yarlagadda, J. Hoque, J. Haldar
Chem. Commun. 2013, 49, 9389-9391.
1. Cleavable cationic antibacterial amphiphiles: Synthesis, mechanism of action, and cytotoxicities
J. Hoque, P. Akkapeddi, V. Yarlagadda, D. S. S. M. Uppu, P. Kumar, J. Haldar
Langmuir 2012, 28, 12225-12234.
Medicinal Chemistry and Drug Discovery Laboratory
